# Yorvipath

NDC: 73362-101
Generic name: Palopegteriparatide
Labeler / Manufacturer: Ascendis Pharma, Endocrinology, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: INJECTION, SOLUTION
Routes: SUBCUTANEOUS
Marketing started: 20240809

FDA application: NDA216490

## Active ingredients

- PALOPEGTERIPARATIDE: 294 ug/.98mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"73362-101"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=73362-101
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1fa23fd-c434-443e-9a17-5750578c8602